Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Management of skin toxicity of epidermal growth factor receptor inhibitors

Management of skin toxicity of epidermal growth factor receptor inhibitors Epidermal growth factor receptor (EGFR)-targeted therapies (monoclonal antibodies such as cetuximab and panitumumab as well as tyrosine kinase inhibitors like erlotinib and gefitinib) are responsible for a unique constellation of mechanism-based, class-specific side effects on the skin. Besides the well-known acneiform eruption, this skin toxicity consists of xerosis (leading to eczema and fissures), paronychia, hair changes, telangiectasia, hyperpigmentation, and mucosal changes. Dermatologic treatment is supportive and aims at maintaining quality of life while continuing EGFR-inhibitor therapy. Although a recent study demonstrated the effectiveness of prophylactic minocycline in cetuximab-induced acneiform eruption, randomized controlled trials remain sparse and evidence-based guidelines are lacking. Based on personal experience, most cases of acneiform eruption are well controlled by topical metronidazole and oral minocycline 100 mg qd. For severe reactions, minocycline dose is doubled and saline compresses have proven very valuable. For superinfection with Staphylococcus aureus, oral cefuroxim axetil can be added for a short term. Emollients and topical steroids can be administered for skin dryness or eczema. Paronychia is the hardest part to treat but antiseptic soaks and a corticosteroid paste can alleviate symptoms to some degree. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Targeted Oncology Springer Journals

Management of skin toxicity of epidermal growth factor receptor inhibitors

Segaert, Siegfried
Targeted Oncology , Volume 3 (4) – Oct 1, 2008
Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/management-of-skin-toxicity-of-epidermal-growth-factor-receptor-WPfAsfETEq

References (26)

Publisher
Springer Journals
Copyright
Copyright © Springer-Verlag 2008
Subject
Medicine & Public Health; Biomedicine general; Oncology
ISSN
1776-2596
eISSN
1776-260X
DOI
10.1007/s11523-008-0092-7
Publisher site
See Article on Publisher Site

Abstract

Epidermal growth factor receptor (EGFR)-targeted therapies (monoclonal antibodies such as cetuximab and panitumumab as well as tyrosine kinase inhibitors like erlotinib and gefitinib) are responsible for a unique constellation of mechanism-based, class-specific side effects on the skin. Besides the well-known acneiform eruption, this skin toxicity consists of xerosis (leading to eczema and fissures), paronychia, hair changes, telangiectasia, hyperpigmentation, and mucosal changes. Dermatologic treatment is supportive and aims at maintaining quality of life while continuing EGFR-inhibitor therapy. Although a recent study demonstrated the effectiveness of prophylactic minocycline in cetuximab-induced acneiform eruption, randomized controlled trials remain sparse and evidence-based guidelines are lacking. Based on personal experience, most cases of acneiform eruption are well controlled by topical metronidazole and oral minocycline 100 mg qd. For severe reactions, minocycline dose is doubled and saline compresses have proven very valuable. For superinfection with Staphylococcus aureus, oral cefuroxim axetil can be added for a short term. Emollients and topical steroids can be administered for skin dryness or eczema. Paronychia is the hardest part to treat but antiseptic soaks and a corticosteroid paste can alleviate symptoms to some degree.

Journal

Targeted Oncology – Springer Journals

Published: Oct 1, 2008

Keywords: Acneiform eruption; Cetuximab; Epidermal growth factor receptor (EGFR); inhibitors; Erlotinib; Panitumumab; Paronychia

There are no references for this article.